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Abstract: 
 
The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene is an 
important predictive biomarker for benefit from alkylating agent therapy in glioblastoma. 
Recent studies in anaplastic glioma suggest a prognostic value for MGMT methylation. 
Investigation of pathogenetic and epigenetic features of this intriguingly distinct behavior 
requires accurate MGMT classification to assess high throughput molecular databases. 
Promoter methylation-mediated gene silencing is strongly dependent on the location of the 
methylated CpGs, complicating classification. Using the HumanMethylation450 (HM-450K) 
BeadChip interrogating 176 CpGs annotated for the MGMT gene, with 14 located in the 
promoter, two distinct regions in the CpG island of the promoter were identified with high 
importance for gene silencing and outcome prediction. A logistic regression model (MGMT-
STP27) comprising probes cg1243587 and cg12981137 provided good classification 
properties and prognostic value (kappa=0.85; logrank p<0.001) using a training-set of 63 
glioblastoma from homogenously treated patients, for whom MGMT methylation was 
previously shown to be predictive for outcome based on classification by methylation-specific 
PCR. MGMT-STP27 was successfully validated in an independent cohort of chemo-
radiotherapy treated glioblastoma patients (n=50; Kappa=0.88; outcome, logrank p<0.001). 
Lower prevalence of MGMT methylation among CpG island methylator phenotype (CIMP) 
positive tumors was found in glioblastoma from The Cancer Genome Atlas than in low grade 
and anaplastic glioma cohorts, while in CIMP-negative gliomas MGMT was classified 
methylated in approximately 50% regardless of tumor grade.  
The proposed MGMT-STP27 prediction model allows mining of datasets derived on the HM-
450K or HM-27K BeadChip to explore effects of distinct epigenetic context of MGMT 
methylation suspected to modulate treatment resistance in different tumor types. 
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Introduction 
High throughput platforms for genome wide DNA methylation analysis have allowed 
establishing the methylome of large series of patient samples. Pattern analysis of respective 
datasets have identified CpG island methylator phenotypes (CIMP) for several tumor types 
such as colon cancer [19,21,42] and more recently also glioma (G-CIMP) [29,43,45]. 
However, classification of samples as being silenced by aberrant methylation for a given gene 
is not obvious, since the relationship between CpG-methylation at individual sites, the extent 
of the overall CpG island methylation, and their effect on gene silencing is strongly dependent 
on the location within the gene [46]. Promoter methylation of the repair gene O6-
methylguanine-DNA methyltransferase (MGMT) is a predictive factor for benefit from 
alkylating agent therapy in glioblastoma patients [3,16,33]. The predictive value of the 
MGMT status is supported by recent findings in two clinical trials, comparing radiotherapy 
versus temozolomide (TMZ) treatment. In these trials for elderly patients retrospective 
analysis of the MGMT methylation status was associated with prediction of good outcome in 
the TMZ-, but not the RT-arm [24,52]. Furthermore, the MGMT status has been prospectively 
validated in a phase III trial as biomarker for favourable outcome in glioblastoma patients 
treated with temozolomide [12]. Repair by MGMT reverses alkylation at the O6-position of 
guanine, one of the most toxic lesions induced by alkylating agents such as temozolomide 
(TMZ), thereby blunting the treatment effect [18,30]. Hence, the MGMT methylation status 
has become a biomarker used for patient stratification or patient selection in clinical trials for 
glioblastoma patients [12,39,50]. Surprisingly, recent studies in anaplastic glioma (WHO 
grade III) suggest a prognostic value [44,51]. In order to investigate pathogenetic and 
epigenetic features associated with this intriguingly distinct behaviour of anaplastic glioma 
compared to glioblastoma, it is of high interest analyzing large datasets of glioma for which 
DNA methylome data has been reported, and classifying them by their MGMT gene promoter 
methylation status for integration into multi-dimensional molecular and clinical data analysis. 
Several glioma datasets comprising methylome data obtained on the Infinium 
HumanMethylation27 (HM-27K) or HM-450K BeadChip that interrogate at single-nucleotide 
resolution over 27,000 or 485,000 methylation sites per sample, respectively, have become 
publicly available [7,29,43,45]. The most comprehensive glioblastoma dataset with over 200 
samples is from The Cancer Genome Atlas [29,40], widely used for hypothesis generation and 
validation in brain tumor research [17,48,53], however, the MGMT methylation status has not 
yet been annotated. 
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The objective of this study was to propose a model determining the probability of 
MGMT promoter methylation allowing classification into methylated and unmethylated 
samples based on CpG methylation data obtained on the widely used HM-450K or HM-27K 
BeadChip. The model can be applied to other datasets for example to further investigate of the 
relationship of MGMT methylation with CIMP and other molecular and clinical parameters. 
The basic idea was to train the model using methylation-specific PCR (MSP) based 
classification that we have shown to predict favorable outcome in a homogenously and 
prospectively treated glioblastoma patient population and for which we have obtained HM-
450K data [15,16]. Standard treatment included the alkylating agent temozomoide (TMZ) 
concomitant with and adjuvant to radiotherapy [36,38]. At the same time this study allowed 
investigation of the relationship between location specific CpG methylation, MGMT gene 
expression and outcome, supporting the mechanistic hypothesis that methylation dependent 
gene silencing results in loss of expression and subsequently benefit from alkylating agent 
therapy in glioblastoma.  
 
Material & methods 
Patient samples and external data sets  
 DNA methylation profiles were established for 63 glioblastoma tissues from 59 
patients and five non-tumoral brain tissues (epilepsy surgery). All glioblastoma patients were 
treated within a phase II or a randomized phase III trial [36,38] and provided written informed 
consent for molecular studies of their tumors. The protocols were approved by the ethics 
committees at each participating center and the respective competent authorities. For this 
patient cohort (M-GBM) that served as training set, detailed clinical information, treatment 
[37], and molecular data was available, including gene expression data [26], and the MGMT 
methylation status based on classic methylation-specific PCR (MSP) [15,16].  
Four external glioma DNA methylation datasets associated with clinical information 
were used: The first, prospectively collected glioblastoma samples of a cohort of 50 patients 
(E-GBM) treated with combined chemo-radiotherapy with TMZ (Stupp protocol) for which 
HM-27K and methylation-specific pyrosequencing-based (MS-PSeq) MGMT methylation 
information was available [7] (see supplementary Figure S1 for location of 5 interrogated 
CpGs). The second dataset with HM-27K information consisted of 241 glioblastoma samples 
(TCGA-GBM, survival information available for 239 samples) and was downloaded from 
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The Cancer Genome Atlas (TCGA) website (http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) 
[29,40]. The third comprised HM-27K data from 67 anaplastic glioma (WHO grade III) (VB-
Glioma-III) [45] of a cohort of homogenously treated patients, including MGMT methylation 
classification based on methylation-specific multiplex ligation-dependent probe amplification 
(MS-MLPA) (see Figure S1 for location of the 3 interrogated CpGs, probes used are 
described [44]). The fourth dataset comprised 71 low grade and anaplastic glioma samples (29 
WHO grade II and 42 grade III) profiled on the HM-450K (T-Glioma-II/III) [43].  
 
DNA methylation analysis 
DNA was isolated from frozen tissues whereof 1.0 g DNA was converted by bisulfite 
using the EZ DNA Methylation™ Kit (# D5001 Zymo Research Corporation) according to 
the manufacturer’s instructions. DNA methylation analysis was performed on the HM-450K 
(Illumina) as recommended at the Genomics platform at the University of Geneva. For each 
interrogated CpG two site-specific probes are present, one designed for the methylated and 
another for the unmethylated locus to which the chemically converted DNA gets hybridized. 
Single-base extension of the hybridized probes incorporates a labeled ddNTP, which allows 
subsequent quantification of methylated and unmethylated alleles 
(http://www.illumina.com/technology/infinium_methylation_assay.ilmn).  
 
Data analysis 
The intensities of methylated and unmethylated signals were normalized using the 
Illumina GenomeStudio program. In the annotation file 176 CpG probes were associated with 
the MGMT gene, whereof 25 are shared with the HM-27K that was used in three of the four 
external datasets. The DNA methylation information was summarized by M-values as 
recommended by Du et al. [4]: 
      



10,max
10,max
+signalA
+signalBlog2=valuesM  
The terms 'signal A' and 'signal B' correspond to the intensities of the unmethylated and 
methylated probes.  
 
Statistical methods 
The relationship between the methylation status of the MGMT promoter defined by 
MSP and the probes located in the MGMT promoter region (CHR10: 131264700-131266300, 
genome build 37) (Figure 1, S1) present on the HK-450K was evaluated by logistic 
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regressions [25,28]. A two-step procedure was used to construct the model to calculate the 
probability of MGMT promoter methylation for subsequent binary classification. In the first 
step, all univariate models were tested and only probes significantly associated with the MSP 
classification were selected using the loglikelihood ratio test (LRT) and Bonferroni correction 
for multiple testing. In a second step, we determined the optimal model built by stepwise 
logistic model building based on the corrected Akaike’s criterion (AICc) [1,20,47] that limits 
overfitting. Two models were constructed, one with all selected probes, and one using only 
the probes common to both, the HM-27K and the HM-450K platforms. The model 
performance was assessed by internal-validation based on a bootstrap procedure with 
optimism/bias correction [13]. This procedure validates the process used to fit the original 
model and it provides a bias value defined by the difference between the index from the 
original dataset and the average of indices from the resampling procedure (200 repetitions). 
The Kappa index and the proportion of correct classification were used to evaluate the 
concordance between the observed and the predicted methylation status. The M-value 
distributions of the probes selected by the model were compared by pairwise quantile-quantile 
representation (QQ-plot) test for the five datasets and non-parametric Smirnov-Kolmogorov 
test for equal distribution. 
For the external datasets, the probability of MGMT promoter methylation and 
subsequent classification were determined using the model compatible with the HM-27K 
platform. The probability values were associated with Wald-based confidence intervals (CI 
95%) to evaluate the uncertainty of the model [9]. CIMP positive tumors were identified using 
unsupervised clustering methods similar to Noushmehr et al. and Turcan et al. [29,43]. The 
relationship between the predicted MGMT status and presence of CIMP was assessed by chi-
squared tests with p-values computed by Monte Carlo simulation, because cell counts were 
expected to be inferior to five [31].  
The Kaplan-Meier (KM) curves and log-rank tests were estimated for each dataset and 
predictor [13,41]. Univariate and multivariate survival models were assessed using the Cox 
proportional hazards regression model and the log-likelihood ratio test (LRT).  
Analyses and graphical representations were performed using R-2.14.2 and the R 
packages design and survival [32]. 
BADY et al ANP-D-12-00286-R 17/09/2012 
 - 8 -  
Results 
Calibration model to predict the methylation status of the MGMT promoter using the 
HM-450K platform  
The prediction model is based on a glioblastoma patient cohort treated with standard 
chemo-radiotherapy within two prospective clinical trials. The MGMT promoter methylation 
status of this cohort was available from classic MSP discriminating methylated and 
unmethylated samples. Most importantly, the results of this MSP-test have been shown to be 
of predictive value for benefit from the addition of temozolomide chemotherapy 
[15,16,26,37]. The results of the MSP assay were considered as reference for model 
construction. A total of 63 glioblastoma samples (M-GBM) and five non-tumoral brain tissues 
were analyzed on the HM-450K beadarray platform. The five non-tumoral brain tissues were 
classified as MGMT unmethylated based on MSP. The clinical and molecular information of 
patient samples is summarized in Table S1. Of the 176 CpG probes on the HM-450K 
annotated as mapping to the MGMT gene, 14 are in the CpG island located in the MGMT 
promoter region encompassing the transcription start site (TSS) (Figure 1). This CpG island 
has been shown to be determinant for regulation of expression [8,23,27,35]. The remaining 
CpGs are mostly found in the MGMT gene body (Supplementary Figure S2). The detection 
call rate for these 14 CpG island-associated probes was equal to 1.00, indicating reliable 
detection. 
 
Association of probes with MSP, MGMT expression, and outcome 
Eleven probes located in the TSS-encompassing CpG island of the MGMT promoter 
were significantly associated with the previously MSP-defined MGMT methylation status 
(Figure 1). We observed two prediction peaks. The strongest association was reached by the 
probes cg12434587 and cg12981137, respectively (No. 10 and 16 in Figure 1). Of note, the 
CpG tested by the probe cg12981137 (CHR 10: 131265575, genome build 37) is also 
interrogated by the reverse primer of the MSP assay (Supplementary Fig. S1) [6]. Strikingly, 
the highest negative correlation between methylation and gene expression (estimated by 
Affymetrix U133plus2, [26]) was observed for the same two probes (Spearman correlation 
coefficients -0.543 and -0.571, respectively). The negative correlation is consistent with 
promoter methylation mediated down-regulation of MGMT expression. Similarly, these two 
probes were the most negatively correlated with MGMT gene expression in the E-GBM and 
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the TCGA-GBM dataset for which expression data was available (Supplementary Fig. S3). 
The association of MGMT expression and DNA methylation at individual CpGs is visualized 
in a scatter plot for the M-GBM data set including non tumoral brain tissues in the 
Supplementary Figure S4. Remarkably, the probes, in vicinity to the TSS (probes 12-14 in 
Figure 1) were at best weakly associated with the MSP results (Figure 1). The strongest 
association with overall survival (OS) peaked at the same two probes, cg12434587 and 
cg12981137, with p-values of <10-5 and <10-4, while again no association was found at CpGs 
in the vicinity of the TSS, and the 5’and 3’ edges of the CpG island (Figure 1). The p-values 
for OS prediction of these two probes were similar to the one for the MSP-based methylation 
classification (p<10-5). The association of OS with methylation at individual CpGs is shown 
for all datasets in Figure S3. Taken together, the CpG methylation probes (8, 9, 10 and 16) 
most correlated with expression also correspond to the probes highly associated with survival, 
and most correlated with MSP-based MGMT methylation prediction.  
In order to test if other methylated CpGs are relevant for MGMT silencing we 
investigated the remaining CpGs, mainly located in the gene body. No negative correlation 
was observed between methylation and expression and no association with outcome 
(Supplementary Figure S2). 
 
Stepwise model building 
We aimed at building an optimal methylation predictor using multiple probes. In the 
first step, the 11 probes significantly associated with MSP-defined methylation were selected. 
The prediction performances with individual probes were very high. Expectedly, the highest 
sensitivity and specificity values were obtained for the probes cg12981137 and cg12434587 
(0.906 and 0.944; 0.875 and 0.944) (Figure 1). Nonetheless, stepwise model building (see 
methods) indicated that MSP assay classification could be predicted even better using two or 
more probes. 
The best model based on probes shared with the HM-27K platform (see Figure 1) 
comprised the two probes cg12434587 and cg12981137 (MGMT-STP27 model). The 
adjustment of the model was of high quality (supplementary Table S2). The sensitivity and 
specificity were equal to 0.969 and 0.889 respectively (Figure 2). The proportion of correct 
classification (0.926), the Kappa index (0.853), and the AUC (0.974) confirm the good 
performance of the model. The hazard risks (HR) based on MSP and the MGMT-STP27 
model were similar (logrank test for both, P<0.001; MSP, HR = 0.229, 95% confidence 
BADY et al ANP-D-12-00286-R 17/09/2012 
 - 10 -  
interval (CI 95%) = [0.115, 0.454]; MGMT-STP27, HR=0.277, CI 95% = [0.145, 0.529]) 
(Figure 2). The equation for this model is given below: 
 	
The methylation probability y can be computed by using the inverse logit function. For 
classification, we used a probability cut-off of 0.358, which empirically maximized the sum 
of sensitivity and specificity (supplementary Table S2; annotation of M-GBM sample 
classification supplementary Table S1). The classification by STP27 and MSP is visualized in 
Figure 2a. Furthermore, the classification by STP27 is projected onto the scatter plots 
comparing expression and DNA methylation at individual CpGs, reclassification from MSP-
based prediction are indicated (Supplemental Figure S4). 
 
The second model, obtained by using all 11 probes available on the HM-450K 
platform contained 4 probes: the two probes also selected in MGMT-STP27 (cg12981137, 
cg12434587) plus cg02022136 and cg23998405. The improvement over MGMT-STP27 is 
only marginal (inferior to 1 unit of the AICc, supplementary Table S2). However, the latter 
model showed a high inflated variance factor (8.9, supplementary Table S2) that reflects a 
problem of multi-colinearity. Consequently, this model was not considered for further 
analyses.  
The internal validation based on the bootstrap procedure showed that the model 
MGMT-STP27 was relatively stable. The unbiased diagnostic accuracy (proportion of correct 
classification) was estimated to 91.24%, against 92.65% initially computed on the original 
dataset. For the Kappa index, the difference between unbiased and original value was only 
equal to 0.03 units (supplementary Table S3).  
External validation of MGMT-STP27 
We validated the use of the MGMT-STP27 model in an external data-set of 50 glioblastoma 
(E-GBM) analyzed on the HM-27K [7]. We dichotomized the MS-PSeq information of the 
MGMT promoter available for 47 cases into methylated and unmethylated. The cut-off was 
estimated at 7.28% average methylation based on a fitted regression model visualized in 
supplementary Figure S5 which is similar to previous reports applying a cut-off of 8% using 
the same MS-PSeq kit [10,33]. The correspondence between the predicted status of MGMT 
promoter methylation using MGMT-STP27 and MS-PSeq information was very high, as 
visualized in Figure 3a with a proportion of correct classification of 0.936, a Kappa index of 
0.875, and sensitivity and specificity equal to 0.931 and 0.944, respectively. Outcome 
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prediction using MS-PSeq information or MGMT-STP27 was as follows: p=0.019, HR = 
0.454, CI 95% [0.232; 0.891] for MS-PSeq, and p< 0.001, HR = 0.305, CI 95%= [0. 156; 
0.596] for MGMT-STP27) (Fig. 3). 
Next we tested the model in a dataset from a cohort of anaplastic oligodendroglioma 
and anaplastic oligoastrocytoma (WHO grade III) (VB-Glioma-III, n=67) generated with the 
27K-platform [45]. The methylation status of the MGMT promoter was available from MS-
MLPA for most cases (n=62). We observed a good concordance (Fig. 3d) with a good 
classification rate of 0.839, a Kappa index of 0.628, and sensitivity and specificity equal to 
0.975and 0.609, respectively. As reported by van den Bent et al. [45], MGMT methylation as 
determined by MS-MLPA was significantly associated with favorable outcome of the patients 
with a p-value of 0.031 (log-rank test) (HR= 0.527, CI 95%=[0.292, 0.952]). This is similar to 
the prediction by our MGMT-STP27 model with a p-value of 0.029 (HR= 0.500, CI 
95%=[0.266, 0.941]) as visualized in Figure 3.  
 
Prediction of MGMT methylation status in TCGA-GBM cohort and a glioma grade II & 
III data set 
The good performance of the MGMT-STP27 model in the two external data-sets 
suggests that we can appropriately predict the MGMT methylation status using common 
probes between the HM-450K and HM-27K platform. Prediction of the MGMT methylation 
status in 241 glioblastoma available from TCGA (TCGA-GBM) with HM-27K data, revealed 
a methylation frequency of 50% (120/241) (see annotation of samples in supplementary Table 
S4 that also includes more recent samples analyzed on the HM-450K platform) similar to our 
M-GBM cohort. Patients from the TCGA-GBM dataset (n=239) with a MGMT methylated 
glioblastoma had a more favorable outcome (p-value=0.047, log-rank test, Figure 4). The HR 
for the predicted methylation status was equal to 0.737 (CI 95% = [0.545, 0.997]).  
The prediction of the MGMT methylation status using MGMT-STP27 in a cohort of 
grade II and III gliomas (T-Glioma-II/III) with HM-450K data, determined a methylation 
frequency of 79% (32/42) in grade III glioma and 86% (25/29) in grade II. The favorable 
outcome associated with MGMT methylation was confirmed as visualized in Figure 4.  
 
Associations of MGMT methylation across tumor grades of glioma  
Next we asked whether MGMT is part of the genes associated with CIMP using the TCGA-
GBM data set [29]. Glioblastoma with a methylated MGMT promoter were significantly 
enriched among CIMP cases (15/20, 75% against 105/221, 48%; p-value = 0.023, Table S5). 
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However, the two MGMT probes selected in our prediction model do not cluster with the 
CIMP core genes as visualized in the heatmap of supplementary Figure S6. Classification of 
the glioblastoma into the three methylation clusters (CIMP+, and 2 non-CIMP clusters) as 
published by Noushmehr et al. [29] were available for 81 samples with HM-27K DNA 
methylation (Fig. 5, Supplementary Fig. S6). The 10 CIMP+ samples defined by the authors 
were all in the CIMP cluster obtained by unsupervised clustering methods in the present 
study. The distribution of samples with methylated MGMT was not significantly different for 
the two non-CIMP methylation clusters (p=0.214, Monte Carlo simulation) defined by 
Noushmehr et al. [29]. 
No association was found between the MGMT status and any of the expression-based 
glioblastoma subtypes proposed by Verhaak et al. [48] (p= 0.518, Monte Carlo simulation) 
(Fig. 5; Table S5). 
In contrast, in both the VB-Glioma-III and the T-Glioma-II/III datasets basically all 
tumors clustering together displaying CIMP were classified as MGMT methylated by the 
MGMT-STP27 model (32/32 and 48/49), while the CIMP negative tumors exhibited a 
methylation frequency of 54% (19/35) and 50% (11/22) that is similar to the three 
glioblastoma datasets (Figures 5 & 6). Hence, the association of methylated MGMT with 
CIMP was much stronger in low grade and anaplastic glioma than in the TCGA-GBM. The 
difference is highly statistically significant (chi-squared test with p-value estimated by Monte 
Carlo simulation; 32/32 vs 15/20, p-value < 0.005 for VB-Glioma-III and 48/49 vs 15/20, p-
value < 0.005 for T-Glioma-II/III). In the VB-Glioma-III dataset this association was retained 
when using the CIMP classification published by van den Bent and colleagues (MGMT 
methylated among CIMP+, 30/30; Figure 5).  
 
Comparisons of M-value distribution across datasets and platforms 
The pairwise comparisons of the M-value distribution for the two probes cg12434587 
and cg12981137 across datasets revealed that M-values were generally higher in the grade 
II/III glioma (VB-Glioma-III, T-Glioma-II/III) as compared to glioblastoma (M-GBM and 
TCGA-GBM) (p-values <0.05 from Kolmogorov-Smirnov tests, supplementary Figure S7). 
However, the comparisons between the glioblastoma datasets, analyzed on the HM-450K (M-
GBM) and the HM-27K (TCGA-GBM), respectively, showed similar M-values distributions 
(p=0.260 and p=0.145, supplementary Figure S7). Likewise, the M-value distributions among 
the datasets of grade II and III gliomas analyzed on the HM-27K (VB-Glioma-III) and the 
HM-450K (T-Glioma-II/III), respectively, were similar (p=0.435 and p=0.233, supplementary 
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Figure S7). Hence, indicating that differences observed between the studies were not due to a 
platform effect, but rather result from biological differences. Consequently, this could affect 
(bias) the prediction quality of the methylation status of MGMT for grade II and III glioma by 
MGMT-STP27, and may explain the higher number of positive calls by MGMT-STP27 when 
compared to MS-MLPA (specificity of only 0.609 when using MGMT-STP27 as predictor of 
MS-MLPA methylation calls). However, outcome prediction was equally good for both 
methylation call methods in the VB-Glioma-III data (Fig. 3). 
Discussion 
The analysis of the MGMT gene in glioblastoma using HM-450K methylation data has 
shown a strong CpG location dependent effect on patient outcome. To our knowledge, this is 
the first report describing the spatial relationship of CpG methylation in the MGMT promoter 
and the gene body and outcome of patients treated with alkylating agent therapy. Two regions 
of methylated CpGs with strong association to patient survival were identified (p< 0.0001 
after Bonferroni’s correction) separated by a prediction minimum at the TSS. The two 
identified regions were also associated with the strongest negative correlation to MGMT gene 
expression, consistent with CpG methylation mediated gene silencing and consequent 
sensitization to alkylating agent therapy due to lack of MGMT mediated repair in this 
homogenously treated patient population. The two regions identified encompass the 
differentially methylated regions 1 and 2 (DMR1 and 2, Figure 1) proposed by Malley et al. 
[23] to be most relevant for gene silencing when methylated in glioblastoma cell lines and 
xenografts. Shah et al. [35] defined 3 relevant regions, of which R2 and R3 encompass DMR1 
and 2, and methylation of two of these three regions were associated with favorable 
progression free survival in their population of 44 glioblastoma patients treated with RT and 
concomitant and adjuvant TMZ. Most importantly, the region interrogated for diagnostic 
purposes using MSP [5,16] overlaps with the CpGs associated with best outcome prediction 
identified here. In contrast, none of the 161 CpGs interrogated outside the CpG island, located 
mostly in the gene body, showed an association with outcome, or a negative correlation with 
MGMT expression (Supplementary Figure S2). However, we cannot exclude that other CpGs 
may be more relevant as the once described here, since the BeadChip array does not 
interrogate all CpGs of the CpG island encompassing the MGMT promoter (Supplementary 
Fig. S1). 
The CpG methylation probes present on the HM-450K and HM-27K BeadChip identified 
to be most relevant for gene silencing and outcome allowed construction of a model for 
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prediction of the MGMT methylation status. The use of logistic regression provides a simple 
model to calculate the methylation probability for a new sample based on two probes. Its 
ability to compute confidence and prediction intervals [2,20] may be of particular interest for 
treatment decisions for patients whose tumors display methylation probabilities close to the 
cut-off (Figures 2-4). This allows application of a “safety margin” as we do in EORTC26082 
(NCT01019434) that selects unmethylated glioblastoma patients only (cut-off set at lower 
bound of 95% CI using a quantitative MSP assay [49]), since it omits TMZ, thereby limiting 
the risk to withhold TMZ in patients who may potentially profit from it. The model’s good 
performance is reflected in similar or improved prediction of OS as compared to the MSP-
based classification or MS-PSeq-based prediction in the E-GBM validation set, in accordance 
with high values for good classification, Kappa-value, and sensitivity and specificity measures 
(Figures 2 & 3). 
Our model can be used for both the HM-450K and the HM-27K BeadChip. The platform 
effect was very weak. A higher amplitude of the methylation signal was detected in the low 
grade and anaplastic glioma samples that may simply reflect the fact that in non-glioblastoma 
usually both MGMT copies are present, while in glioblastoma only one is methylated and the 
other one is lost due to the characteristic high frequency of deletions of chromosome 10 that 
reached 90% in the M-GBM samples [22]. Consequently, presence of two methylated MGMT 
copies will lead to an increase of the ratio methylated to unmethylated alleles. For the model, 
however, this may generate a bias in the estimation of MGMT methylation probabilities based 
on the MGMT-STP27 model for non-glioblastoma tumors. The estimation could be improved 
by determining new optimal parameters in this population. Nevertheless, despite these 
limitations classification using the MGMT-STP27-based outcome prediction of the VB-
Glioma-III dataset was similar to the one reported by the authors who used another method of 
MGMT testing (Figure 3). Prediction of the MGMT status in the TCGA-GBM confirmed a 
favorable outcome for patients with MGMT methylation, although the effect was weaker than 
in our homogenously treated cohort (M-GBM) and the E-GBM cohort in which all patients 
were treated with combined chemo-radiotherapy comprising TMZ. This is not surprising, 
since most patients in the TCGA cohort had not (yet) been treated according to the current 
standard of care of combined chemo-radiotherapy (collection before 2005), and many 
different types of therapy were reported for the patients in the respective annotation file [29].  
The annotation of the MGMT status in the TCGA-GBM dataset according to MGMT-
STP27 allowed determining that MGMT is not a CIMP gene in glioblastoma although CIMP 
tumors were more likely to be MGMT methylated. Further, the prevalence of MGMT 
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methylated glioblastoma is not different in the 2 non-CIMP methylation clusters defined by 
Noushmehr et al. [29], nor are they enriched in any of the expression-based glioblastoma 
subtypes, suggesting that MGMT methylation is not associated with a particular pathogenetic 
mechanism involved in the development of de novo glioblastoma.  
This is in contrast to grade II and III glioma (VB-Glioma-III and T-GliomaII/III) in which 
MGMT is methylated in basically all CIMP tumors according to our classification model. It 
has been proposed that MGMT methylation may represent an epiphenomenon of CIMP in the 
context of grade III glioma [45]. This association of with CIMP with MGMT methylation may 
provide the key to understand why MGMT methylation is associated with a prognostic and not 
a predictive value for benefit from alkylating agent containing chemotherapy in anaplastic 
glioma as suggested by two independent clinical trials [44,51]. Most of the VB-Glioma-III 
samples analyzed here in fact originate from one of these two studies and were characterized 
for CIMP [45]. Anaplastic gliomas with CIMP accumulate other known favourable prognostic 
factors such as mutations of the isocitrate dehydroxygenase (IDH) genes, 1p/19 co-deletions, 
and also MGMT promoter methylation, plus a plethora of other methylated genes whose 
contribution to response to therapy remains to be explored and exploited. It has become clear 
that these CIMP positive tumors represent a pathogenetically different disease driven by 
epigenetic alterations mediated in most cases by IDH1/2 mutations [11,43]. Interestingly, 
non-CIMP anaplastic gliomas showed a MGMT promoter methylation frequency similar to 
glioblastoma. It remains to be seen if in this CIMP negative patient subpopulation the MGMT 
status is predictive for benefit from alkylating agent therapy like in glioblastoma or has a 
prognostic value. This question can be addressed in the ongoing CATNON trial (EORTC 
26053-22054; NCT00626990) for anaplastic glioma comparing radiation therapy with or 
without temozolomide. The same question applies to low grade glioma where radiation versus 
temozolomide treatment is tested (EORTC 22033-26033, NCT00182819) and the role of 
CIMP and MGMT methylation will need to be dissected. Since the HM-450K BeadChip 
allows the use of paraffin embedded tumors, comprehensive DNA methylation analysis of 
samples collected within these clinical trials has become feasible. 
The proposed MGMT-STP27 MGMT classification model will allow investigation of 
distinct epigenetic features associated with MGMT silencing in the context of CIMP positive 
or CIMP negative gliomas by multidimensional analysis of respective molecular and clinical 
data. Such alterations likely modulate response to therapy and may be exploited for 
improvement of personalized therapy.  
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Figure Legends 
 
Figure 1. CpG methylation of the MGMT promoter region, MGMT expression and patient 
survival in M-GBM. (a) The Spearman and Pearson correlation between gene expression 
(probe 204880_at from Affymetrix U133plus2) and M-values of the 18 CpG methylation 
probes from the Infinium humanmethyltion 450K BeadChip (HM-450K) of the M-GBM 
cohort are visualized on a scale representing the physical location in the CpG island of the 
promoter region encompassing the transcription start site (TSS) (genome build 37). (b) The 
association between overall survival (OS) and CpG methylation of distinct probes are 
displayed (p-values, univariate Cox regression model and log-likelihood ratio test; p-values, 
minus-log10-transformed). The p-value for classification by MSP is indicated at its physical 
location (primer set, red). (c) The association between MGMT promoter methylation 
classification based on MSP and the 18 selected CpG methylation probes from the HM-450K 
are shown (logistic regression and log-likelihood ratio test; p-values, minus-log10-
transformed). The dotted grey lines in b & c correspond to the threshold of 0.05. The graph at 
the bottom indicates the physical location of the TSS (TSS1, according to Harris et al. [14]; 
TSS2 according to gene build 19); the location of the CpG island/ individual CpGs, green; the 
differentially methylated regions 1 and 2, DMR1 & 2, as defined by Malley at al. [23] blue; 
the primers for MSP [6], red; the region for MS-clone sequencing in glioblastoma, MS-CSeq 
[34]; the CpGs interrogated by methylation specific multiplex ligation-dependent probe 
amplification, MS-MPLA, purple [44], and methylation-specific pyrosequencing, MS-PSeq, 
pink [7]. The names of the CpG probes interrogated on HM-450K are given on the right. 
Probes present on both platforms (HM-450K and HM-27K) are indicated by triangles, probes 
only present on the HM-450K are represented by squares. See supplementary Figure S1 for 
exact locations of CpGs interrogated by the different assays. The symbols are explained on 
the right hand side. We note that the CpG methylation probes (8, 9, 10 and 16) most 
correlated with expression also correspond to the probes highly associated with survival, and 
most correlated with MSP-based MGMT methylation prediction. 
 
Figure 2. Performance of the stepwise logistic regression model (MGMT-STP27) for 
prediction of methylation status of the MGMT promoter. (a) displays the estimated probability 
of methylation against the logit-transformed response fitted for the M-GBM dataset. The 
observed values are given by full black squares, indicating same or different classification by 
STP27. Fitted values and their confidence intervals [CI] at 95%, estimated by simulation, 
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correspond to the red line and grey area, respectively. Dark green dotted lines indicate the 
threshold used to define methylated and unmethylated samples. (b) The receiver operating 
characteristic (ROC) curve is provided, where sensitivity (true positive rate) is plotted against 
1- specificity (false positive rate). Accuracy is measured by the area under the ROC curve 
(AUC). Performance criteria are given for the optimal cut-off below the curve: optimal cut-
off, sensitivity (sens), specificity (spec), positive predictive value (pv+), negative predictive 
value (pv-) and area under the curve (auc). The Kaplan-Meier curves for 58 patients are 
displayed for MSP-based classification (c) for the predicted methylation status obtained by 
the MGMT-STP27 model (d), and with additional stratification by treatment arm (RT+TMZ 
or RT treatment arm) (e) to visualize the predictive value of MGMT methylation for benefit 
from TMZ. Results of log-rank tests are given below each survival representation. M, 
methylated; U, unmethylated. 
 
Figure 3. Validation of MGMT-STP27 in external datasets. The plots a and d represent the 
estimated probability of methylation against logit-transformed response fitted for the E-GBM, 
and VB-Glioma-III datasets using STP27. Fitted values and their prediction intervals [PI] at 
95%, estimated by simulation, correspond to the red line and grey area, respectively. Dark 
green dotted lines indicate the threshold used to define methylated and unmethylated samples 
according to STP27. The observed values are visualized by full black squares, indicating same 
or different classification by STP27 or MS-PSeq for E-GBM and MS-MLPA test for VB-
Glioma-III, respectively. The Kaplan-Meier curves are based on classification by MS-PSeq 
for E-GBM (b), the MS-MLPA test for VB-Glioma-III (e), and based on the respective 
predicted methylation status using MGMT-STP27, in (c) and (f). Results of log-rank tests are 
given below each survival representation. M, methylated; U, unmethylated. 
 
Figure 4. MGMT-STP27 based prediction in external datasets. The first plots in (a) and (c) 
represent the estimated values (probability of methylation fitted against response fitted in link 
space) for the GBM-TCGA and T-Glioma-II/III datasets. Fitted values and their prediction 
intervals [PI] at 95%, estimated by simulation, correspond to the red line and grey area, 
respectively. Dark green dotted lines indicate the threshold used to define methylated and 
unmethylated samples. The white squares correspond to the deduced methylation status. The 
Kaplan-Meier curves are based on classification by prediction using MGMT-STP27 for 
TCGA-GBM (b), T-Glioma II/III (d), or only T-Glioma-III (e), Results of log-rank tests are 
given below each survival representation. M, methylated; U, unmethylated. 
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Figure 5. Distribution of MGMT methylation and CIMP status. The dendrogram for each 
dataset is provided. The five datasets were centered and normalized by probes followed by 
unsupervised hierarchical classifications of the 1000 most variable probes (autosomes only) 
using Ward’s algorithm and Euclidean distance to establish CIMP classification (green 
rectangle for non-CIMP and red for CIMP). The methylation status of the MGMT promoter 
predicted by MGMT-STP27, blue for unmethylated, and red for methylated, is provided as 
label. Sample description comprise CIMP status as established in the respective original 
publication (if available), gender, IDH1 status (mutated or not, with additional annotation for 
TCGA-GBM; u, unvalidated; v, validated), classification into methylation clusters according 
to Noushmehr et al. [29] (cluster annotation Level 4 data, TCGA data portal), and gene 
expression based glioblastoma classification using a modified model from Verhaak et al. [48], 
tumor grade (for T-Glioma-II/III), and methylation status of MGMT promoter based on MSP, 
MS-MLPA, and MS-PSeq, unmethylated, light green; methylated, darkgreen. The color code 
for the labels is displayed.  
 
Figure 6. Proportion of predicted MGMT promoter methylation in CIMP+ or CIMP- gliomas. 
For all 5 glioma datasets the proportion of CIMP+ (a), the proportion of MGMT methylation 
(b), and the proportion of MGMT methylation in CIMP+ (c) and CIMP- (d) tumors, 
respectively, is given. The CIMP status and the MGMT promoter methylation status are 
derived from unsupervised classification and MGMT-STP27, respectively.  
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Code TuBa Age Sex OS [months] Status PrGBM TMZ/RT
1076 NA NA NA NA NA NA
1297 36 M 60 dead yes yes
1308 45 F 17 dead yes yes
1316 68 M 9 dead no no
1317 26 M 17 dead yes yes
1357 36 M 28 dead yes yes
1360 65 M 9 dead yes yes
1399 NA F NA NA NA NA
1419 48 F 27 dead no no
1430 37 M 15 dead yes yes
1437 48 M 16 dead yes yes
1496 49 M 10 dead yes no
1497 37 M 15 dead yes yes
1543 27 M 11 dead yes yes
1545 58 M 9 dead yes no
1552 56 M 11 dead yes yes
1562 56 F 23 dead yes yes
1564 45 M 9 dead no no
1566 60 F 15 dead yes no
1584 56 M 17 dead yes yes
1587 60 F 44 alive yes yes
1589 48 M 8 dead yes yes
1591 44 M 37 dead yes yes
1601 55 F 24 dead yes yes
1603 53 M 17 dead yes no
1606 48 F 9 dead yes yes
1612 57 M 10 dead yes no
1613 27 M 11 dead yes yes
1614 49 M 42 dead yes yes
1617 63 M 7 dead yes yes
1621 62 M 25 dead yes yes
1622 62 M 25 dead yes yes
1628 49 F 15 dead yes yes
1639 43 M 16 dead yes no
1646 63 M 15 dead yes yes
1647 44 F 5 dead yes no
1703 48 M 17 dead yes no
1704 48 M 4 dead yes yes
1705 53 M 13 dead yes yes
1706 44 M 9 dead yes no
1707 61 F 12 dead yes yes
1709 41 M 16 dead yes no
1710 43 M 17 dead yes yes
1714 52 M 78 alive yes yes
1729 49 M 16 dead yes no
1730 49 M 15 dead yes no
1731 54 M 15 dead yes no
1732 62 F 5 dead yes no
1748 59 M 6 dead yes no
1749 52 F 33 alive yes no
1752 54 M 23 dead yes no
1755 45 F 6 dead yes no
1756 56 M 8 dead yes no
1758 37 M 18 dead yes yes
1759 53 M 1 dead yes no
1760 63 M 8 dead yes no
1761 51 M 27 dead yes no
1763 62 M 12 dead yes no
1764 32 M 7 dead yes yes
1766 57 M 6 dead yes yes
1768 55 F 6 dead yes yes
1769 52 M 9 dead yes yes
1774 64 M 25 dead no no
1775 52 M 78 alive yes yes
1780 NA NA NA NA NA NA
2900 NA NA NA NA NA NA
2901 NA NA NA NA NA NA
2903 NA NA NA NA NA NA
"Normal" Brain Tissue PatientID MSP‐MGMT IDH1‐status CIMP
yes NB U NA NA
no P‐206 M mut yes
no P‐209 M wt no
no P‐210 M wt no
no P‐216 U wt no
no P‐221 M mut yes
no P‐222 M wt no
no 1399 M NA no
no P‐236 M wt no
no P‐241 M wt no
no P‐240 U wt no
no 55 M mut yes
no P‐241 M wt no
no 106 U wt no
no 94 U wt no
no 236 U wt no
no P‐112 M wt no
no P‐114 U wt no
no 159 U wt no
no 344 U wt no
no 90 M wt no
no 157 U wt no
no 288 M wt no
no 360 M wt no
no 323 M wt no
no 274 U wt no
no 428 M wt no
no 106 U wt no
no 396 M wt no
no 444 M wt no
no P‐113 M wt no
no P‐113 M wt no
no 458 U wt no
no 566 U wt no
no 461 U wt no
no 574 U wt no
no 63 M wt no
no 129 U wt no
no 161 U wt no
no 211 M wt no
no 222 U wt no
no 390 U wt no
no 547 U mut yes
no 57 M wt no
no 83 U wt no
no 147 M wt no
no 242 U wt no
no 97 U wt no
no 345 M wt no
no 527 M wt no
no 246 M wt no
no 15 U wt no
no 283 M wt no
no 12 M wt no
no 84 M wt no
no 254 U wt no
no 284 M wt no
no 328 U wt no
no 356 U wt no
no 506 U wt no
no 558 U wt no
no 563 U wt no
no 100 U wt no
no 57 M wt no
yes NB (rep2) U NA NA
yes NB_BNT_92 U NA NA
yes NB_BNT_104 U NA NA
yes NB_BNT_148 U NA NA
Expression Subtype Trial STP27link STP27response STP27class cg00618725
NA NA ‐1.35414492 0.20519355 U ‐3.42229711
Proneural II 5.24997476 0.99477974 M 1.09732403
Neural II ‐0.56761824 0.36178658 M ‐1.74116
NA II ‐0.58297811 0.35824762 M ‐3.17887999
Mesenchymal II ‐3.92717878 0.01931861 U ‐2.76826385
Proneural II 3.8658949 0.97948549 M 1.43413797
Mesenchymal II 1.67811008 0.84265411 M ‐3.27528806
Proneural  NA 3.80175551 0.97815627 M 0.22313066
NA II ‐0.38279168 0.40545376 M ‐1.53197982
Proneural II 5.34180624 0.99523559 M 0.02092065
Neural II ‐0.46572198 0.38562929 M ‐3.02381719
Proneural III 4.36968733 0.98750296 M ‐0.23950915
Mesenchymal II 5.06517912 0.99372682 M ‐3.10937265
Proneural III ‐3.97314631 0.01846671 U ‐3.50787221
Classical III ‐3.38013919 0.03292196 U ‐3.09603937
Mesenchymal III ‐3.97373131 0.01845611 U ‐3.01859928
Proneural II 4.6035714 0.99008332 M ‐1.7111505
NA II ‐3.31871702 0.03493464 U ‐1.30458223
Proneural III ‐2.72701148 0.06139816 U ‐2.72102712
Mesenchymal III ‐5.34611391 0.00474403 U ‐3.53740425
Classical III 4.43887174 0.98832858 M 1.32309795
Classical III ‐3.27375056 0.03648276 U ‐3.16452472
Mesenchymal III 3.67024901 0.97516249 M ‐0.51676433
Mesenchymal III 2.96603324 0.95101582 M ‐1.82660502
Mesenchymal III ‐2.51025461 0.07514241 U ‐2.82740581
Mesenchymal III ‐4.99719455 0.00671153 U ‐3.04320664
Mesenchymal III 1.99918294 0.88071127 M ‐0.72867908
NA III ‐3.89425067 0.01995242 U ‐3.28360627
Classical III 3.60044961 0.97341464 M ‐3.1260154
Classical III 4.81300059 0.99194201 M 0.79930677
Classical II 5.86416602 0.99716865 M 0.31064419
Classical II 4.26071507 0.98608418 M ‐0.03815013
Classical III ‐2.38167052 0.08458113 U ‐3.04587993
Mesenchymal III ‐4.08917623 0.01647699 U ‐3.05960318
Mesenchymal III ‐3.8032384 0.02181207 U ‐3.09379595
Proneural III 2.01144136 0.88199312 M 0.94539006
Mesenchymal III 1.50081594 0.81769614 M ‐1.68493689
Proneural III ‐3.474633 0.03004268 U ‐3.30444607
Mesenchymal III ‐3.47940737 0.02990387 U ‐3.04351556
Neural III 5.14543137 0.99420778 M 0.4963276
Mesenchymal III ‐3.07583028 0.04411532 U ‐2.82630259
Neural III ‐3.71848851 0.02369552 U ‐3.34218339
Proneural III 1.2900384 0.78415369 M ‐2.26418065
Mesenchymal III 3.80623294 0.97825173 M ‐0.10378648
Proneural III ‐3.85952422 0.02064291 U ‐3.44856061
Classical III 1.45699613 0.81107281 M ‐0.53574595
Classical III ‐1.01876004 0.265269 U ‐2.37698207
Classical III ‐3.38097638 0.03289532 U ‐2.91817331
Classical III 1.37098234 0.79753882 M ‐2.70558527
Classical III 3.71915267 0.97631984 M 0.24825754
Mesenchymal III 4.13618464 0.98426774 M ‐1.01399215
Neural III ‐3.0801818 0.04393218 U ‐3.74179709
Mesenchymal III 1.45901301 0.81138167 M ‐2.39745462
Proneural III 3.64845712 0.97462917 M ‐1.73590387
Mesenchymal III 0.43837652 0.60787212 M ‐3.20495147
Mesenchymal III ‐3.19147156 0.03948793 U ‐3.59023392
Proneural III 6.26194375 0.9980961 M 1.90540162
Classical III 1.37339975 0.79792888 M ‐2.58225903
Classical III ‐3.04611858 0.04538534 U ‐2.90630495
Classical III ‐4.1393187 0.0156838 U ‐3.28995631
Mesenchymal III ‐3.57926522 0.02713911 U ‐2.87748481
Classical III ‐1.91280337 0.12866624 U ‐2.79563828
Neural III ‐2.95286775 0.04960115 U ‐2.9346134
Mesenchymal III 5.46171148 0.99577167 M 1.25706206
NA NA ‐3.97902062 0.01836053 U ‐3.32179977
NA NA ‐2.79232517 0.05774032 U ‐3.226305
NA NA ‐3.40822602 0.03203937 U ‐3.65328891
NA NA ‐1.31857271 0.21105586 U ‐3.04142861
cg01341123 cg02022136 cg02330106 cg02802904 cg02941816 cg05068430 cg12434587
‐1.24331302 ‐2.30658285 1.25765198 ‐6.08330775 ‐1.98029317 ‐6.26007944 ‐4.72584593
‐3.29276153 ‐5.27569998 0.38374859 ‐5.46267489 ‐2.14376015 ‐5.0530342 0.8801676
‐1.55347613 ‐2.25804525 2.15926015 ‐5.54735569 0.45155452 ‐5.0565698 ‐2.88327136
‐3.00928189 ‐4.06119049 1.31436374 ‐5.29848306 ‐1.90856991 ‐4.63636699 ‐5.64469229
‐2.68034904 ‐4.25589508 1.3498265 ‐6.34986568 ‐3.39160967 ‐4.54073952 ‐5.51347848
1.52117568 1.74125473 2.98219195 ‐0.77330803 2.01452877 ‐4.62765511 ‐0.55078194
‐1.81958057 ‐3.1495966 2.11624936 ‐4.52279102 0.87567247 ‐4.26019185 ‐4.7766114
‐0.48891446 ‐0.2013222 1.7653049 ‐5.16273532 ‐2.2989416 ‐4.30882176 ‐1.60886747
‐1.39089607 ‐1.74188071 1.52759921 ‐5.37647083 ‐1.91661813 ‐6.84232896 ‐1.69844285
0.66269592 ‐0.86970213 2.48428783 ‐3.24863698 ‐3.08379968 ‐4.12085594 0.78390984
‐1.39243616 ‐1.35928734 1.94295968 ‐5.20876695 0.03270205 ‐4.72990393 ‐4.22557123
2.06062209 2.62305567 3.21996788 ‐0.33640398 1.15278292 ‐4.13973297 ‐0.48006868
‐2.61214846 ‐2.70348091 2.22149148 ‐3.4032979 ‐2.99450742 ‐6.47806689 0.57256061
‐2.28961864 ‐3.32663649 1.62488604 ‐5.39088103 ‐3.41774554 ‐5.85810598 ‐4.8603404
‐1.29438737 ‐3.75806011 1.12591178 ‐5.73425982 ‐1.37676031 ‐4.33608997 ‐5.19882168
‐2.78362138 ‐5.02298112 0.37922822 ‐5.64665871 ‐3.46791565 ‐4.68833735 ‐5.0786142
‐2.12505211 ‐3.52625885 2.58168104 ‐3.64367367 ‐1.81424622 ‐3.33835064 0.97145088
‐0.5151677 ‐1.05202434 2.70672342 ‐5.28633905 ‐2.49664028 ‐4.53580163 ‐4.5191994
‐2.61831908 ‐2.37823261 0.6766963 ‐5.77373897 2.1372357 ‐4.93795925 ‐4.45593484
‐3.06026448 ‐4.95135737 0.07482011 ‐6.26861763 ‐3.66765279 ‐4.55205349 ‐5.96475641
‐2.31664975 ‐0.06011547 2.87748022 ‐2.91371827 1.16690383 ‐4.37695212 ‐0.46379062
‐2.80084896 ‐4.5985601 0.04615434 ‐5.52534347 ‐2.74540005 ‐6.56872561 ‐5.17307405
‐0.13473334 ‐1.173555 1.26906965 ‐5.49568126 ‐2.99551341 ‐4.94069205 ‐0.55745197
‐1.06658661 ‐0.8961834 1.57124511 ‐1.79234705 ‐0.92070316 ‐3.45804491 ‐0.08918209
‐1.8536612 ‐3.98228517 1.67573846 ‐5.36066011 ‐0.77911172 ‐4.64121929 ‐4.42792432
‐1.52723544 ‐2.88290136 2.02897361 ‐7.6374845 ‐3.17441523 ‐6.51343446 ‐6.03689235
‐2.07166526 ‐2.5273367 1.5657519 ‐5.96523181 ‐1.62636232 ‐4.32457598 ‐4.00343573
‐1.6885261 ‐2.62343665 1.00485209 ‐5.40229514 ‐3.06162809 ‐4.29482258 ‐5.43853533
‐1.56701405 ‐1.85726247 2.39985373 ‐5.57576225 1.32303093 ‐6.24140943 ‐2.87737035
‐1.70189119 ‐3.93609404 2.27224026 ‐5.44048771 1.20524389 ‐4.87099788 0.32522339
0.63388802 1.6399516 2.5658426 ‐1.25334383 ‐1.81052649 ‐3.99074051 1.30021158
0.24558127 ‐0.31446718 1.16750926 ‐2.43492351 ‐2.07254447 ‐4.43018561 0.12978624
‐2.52393693 ‐3.25643439 2.95958814 ‐5.26576313 ‐2.10516251 ‐5.53557447 ‐4.80575946
‐1.03294512 ‐1.88177925 1.83243097 ‐5.39936368 ‐2.06439461 ‐4.69232267 ‐5.89419909
‐3.16911327 ‐4.58221643 0.04293473 ‐4.99448864 ‐3.68330445 ‐4.20761563 ‐5.31487334
0.59947138 0.54312237 1.83727934 ‐1.9828368 ‐0.85620181 ‐4.86400371 0.31352256
1.68598499 2.09802318 2.79159443 ‐3.65186409 ‐2.64964398 ‐4.88301689 ‐1.27956776
‐2.88025733 ‐4.65085846 ‐0.65864294 ‐5.72515546 ‐3.19870744 ‐4.61806698 ‐5.16850152
1.50113948 1.20847235 2.78548391 ‐5.50627697 ‐3.44825269 ‐4.54770216 ‐5.20857816
0.9588049 1.2793946 2.40781018 ‐1.76187934 1.37386702 ‐3.60779922 0.48479812
‐3.07740918 ‐4.51862803 1.49364459 ‐4.92044565 ‐2.60640521 ‐3.8694754 ‐5.00597624
‐3.0477176 ‐5.0540624 0.715179 ‐6.49809065 ‐3.71657749 ‐6.52029776 ‐5.09506504
‐2.26943975 ‐1.74501252 2.43904423 ‐5.13294825 ‐0.1479255 ‐5.06970439 ‐3.27633123
0.3438824 ‐0.37653153 2.01698791 ‐5.24782851 ‐2.318437 ‐4.18840299 ‐0.37021338
‐2.27323243 ‐3.7553132 2.34393327 ‐5.18211083 ‐2.88617569 ‐4.30368645 ‐5.27120362
‐3.1736748 ‐4.59486824 2.73941312 ‐4.98663878 ‐3.21697598 ‐4.18181022 ‐3.441229
‐2.29304192 ‐4.08676468 2.53662617 ‐4.64566196 ‐2.50382003 ‐4.63945735 ‐4.06823364
‐2.61083081 ‐4.70184558 1.56459801 ‐5.41837477 ‐2.86418614 ‐4.80530736 ‐5.4050908
1.05878582 1.05865296 0.94294678 ‐4.22942023 ‐2.30938695 ‐5.4117573 ‐2.67067722
0.61623893 ‐0.05101571 1.9642317 ‐2.17574382 ‐3.24979653 ‐4.8598276 0.0389083
0.12727275 ‐0.40520566 1.37807606 ‐5.36185856 ‐0.69537326 ‐4.77212469 ‐0.08041088
‐1.10178916 ‐1.833752 2.06539323 ‐5.5851723 ‐2.17319528 ‐4.38879608 ‐5.70856635
‐2.08330295 ‐2.87057028 1.89031889 ‐2.14879613 ‐1.1192648 ‐6.1874374 ‐0.8891419
1.41940611 1.28083995 0.34941493 ‐3.35387863 1.24327254 ‐4.38212886 ‐2.58479
0.23338479 ‐0.37101448 0.57101169 ‐3.0164527 ‐1.84858173 ‐6.01378904 ‐4.9350931
‐2.17328639 ‐4.05718086 1.61233555 ‐5.4406775 ‐2.94948193 ‐4.70709406 ‐5.34470588
2.17354109 1.88866229 3.07190811 ‐3.72148326 2.02718011 ‐5.99306449 1.44112755
1.44864394 ‐0.51888033 2.62655741 ‐5.79339013 ‐3.11312054 ‐4.78152468 ‐4.05472219
1.27116322 0.74159674 2.39524334 ‐5.3530726 ‐3.23114583 ‐5.42034881 ‐5.39932986
‐2.69039119 ‐4.46442374 0.39340987 ‐5.46704247 ‐1.82275831 ‐5.05565816 ‐5.04891497
‐2.25283913 ‐3.74256149 0.42560546 ‐5.40839219 ‐3.30479958 ‐6.68552944 ‐5.11760048
‐2.25606201 ‐3.11739554 1.88523909 ‐5.42044403 ‐1.28733317 ‐4.61335863 ‐5.03279757
‐2.18380148 ‐3.99211375 2.42955738 ‐5.39213106 ‐2.50930041 ‐4.72240192 ‐5.25351163
1.16852439 1.44168417 2.32930134 ‐4.41774335 ‐0.46862872 ‐4.87495643 0.94069012
‐1.86524666 ‐2.87933988 0.82356006 ‐6.41515318 ‐2.50805452 ‐5.17257945 ‐5.5649878
‐1.64096101 ‐2.86475781 1.18371381 ‐6.0971581 ‐2.32234186 ‐5.9608646 ‐5.7932301
‐1.48490151 ‐2.56174209 1.25007025 ‐5.58345891 ‐2.4886035 ‐5.28996 ‐5.84544738
‐1.25850068 ‐2.52886794 1.22011678 ‐5.49222368 ‐1.84842574 ‐6.03176775 ‐4.88154898
cg12575438 cg12981137 cg14194875 cg16215402 cg18026026 cg19706602 cg23998405
2.94063939 ‐3.43748691 ‐3.52578691 ‐2.90542426 ‐5.45235981 ‐4.59545205 ‐3.4884984
0.67237709 0.5013628 0.96742175 ‐2.60439879 ‐4.13163652 ‐3.5549326 ‐8.37116203
2.78018779 ‐3.63684587 0.15036375 ‐2.82642165 ‐5.40717538 ‐3.89506119 ‐3.73460751
3.25771097 ‐2.08233417 ‐3.59469919 ‐2.8800804 ‐5.41766502 ‐3.99499353 ‐5.56134411
2.37362904 ‐5.76664893 ‐3.80614056 ‐2.96730784 ‐6.16477803 ‐3.69047907 ‐5.41690306
3.72895904 ‐0.17845603 1.44504504 ‐2.28608612 ‐4.7445545 ‐4.24765435 1.43677475
2.58409593 ‐0.13565042 ‐3.04565956 ‐2.93531687 ‐6.64898933 ‐3.90048877 ‐4.26786004
2.07364244 0.35430347 0.65796208 ‐2.81135131 ‐4.47816818 ‐4.15719458 ‐3.49036678
1.5931547 ‐4.11144764 ‐2.26351185 ‐3.05277513 ‐4.80780881 ‐3.76994085 ‐2.81164915
2.51768114 0.65524899 ‐0.50374591 ‐2.22728261 ‐4.58800296 ‐3.56478462 ‐1.81695205
2.79773451 ‐2.76316916 ‐2.85283986 ‐2.72327477 ‐4.09798264 ‐3.90872337 ‐2.62095125
3.53818964 0.32509537 ‐0.07110419 ‐2.10604375 ‐4.67590044 ‐2.28465722 2.24906215
1.84418865 0.47690899 ‐1.76032407 ‐2.73974511 ‐4.16641995 ‐3.29293251 ‐5.84133361
2.50326922 ‐6.18786361 ‐3.74683415 ‐2.93187379 ‐4.90879389 ‐3.78294793 ‐5.05138408
2.34414583 ‐5.35520738 ‐3.93842061 ‐2.95350838 ‐4.55588267 ‐3.96388971 ‐4.43406082
1.55121051 ‐6.06430972 ‐4.27191579 ‐2.73209584 ‐3.98829714 ‐3.83471853 ‐5.84583403
3.02356944 ‐0.2482867 0.05056125 ‐2.37933733 ‐5.21262854 ‐3.40829735 ‐6.23799638
3.36408777 ‐5.67557581 ‐0.54167761 ‐2.9720465 ‐5.2008265 ‐4.07722833 ‐3.57045874
2.85438026 ‐5.07289491 ‐2.12876826 ‐2.58617813 ‐4.2636354 ‐3.40670249 ‐5.30298653
2.25662846 ‐7.04146703 ‐4.39941871 ‐3.0613683 ‐6.05509857 ‐4.64606191 ‐6.23399242
2.69335094 0.39051033 1.19286725 ‐1.97334075 ‐2.89519827 ‐3.41828511 ‐4.93559768
2.42645639 ‐5.25502259 ‐4.04584461 ‐2.57388397 ‐4.90469591 ‐3.10205431 ‐5.27876078
2.0544692 ‐0.38583732 ‐1.86608378 ‐2.72522039 ‐5.99449606 ‐4.05411926 ‐2.0548677
2.086651 ‐1.41237221 ‐0.5774011 ‐2.2489289 ‐3.05757405 ‐3.71796054 ‐2.95540339
2.51514751 ‐4.85486838 ‐3.34869985 ‐2.75184395 ‐3.92118662 ‐4.13624188 ‐5.28236929
3.26219668 ‐6.6238094 ‐3.8980644 ‐3.10280383 ‐5.30329755 ‐4.06807633 ‐4.16605869
2.33553039 ‐0.22898377 ‐0.17987072 ‐3.0321477 ‐4.8368577 ‐3.51006363 ‐4.44105941
2.16192415 ‐5.77374537 ‐3.42151824 ‐2.88922954 ‐4.30444709 ‐3.9232206 ‐3.86347938
2.94966442 0.85872373 ‐2.45228513 ‐2.86036776 ‐4.20311336 ‐3.82094948 ‐1.87197193
2.23595487 0.34543341 0.66638296 ‐2.92872734 ‐4.97554542 ‐3.77985019 ‐4.99324623
3.07809592 0.9253272 ‐0.165096 ‐2.49160936 ‐4.07948478 ‐2.79192908 0.04217573
1.94313153 ‐0.13949968 ‐0.09206429 ‐2.55369586 ‐4.31795044 ‐3.53948988 ‐0.92216661
3.43469559 ‐4.50111073 ‐3.03426683 ‐2.527247 ‐4.59672221 ‐3.37645589 ‐4.81339384
2.7525316 ‐5.72489737 ‐3.49234094 ‐2.4676176 ‐4.66317133 ‐3.94108502 ‐2.92437802
1.32533687 ‐5.74586521 ‐4.00755954 ‐2.75606396 ‐4.3330902 ‐3.64587774 ‐6.25455109
2.01915469 ‐2.67185504 0.91238442 ‐2.75099102 ‐4.59415555 ‐4.37739463 ‐0.20306521
3.23042947 ‐2.31663622 0.90179666 ‐2.33356344 ‐3.73799572 ‐3.67862681 1.4490455
‐0.57535784 ‐5.47445249 ‐3.93115166 ‐2.77992554 ‐6.19498409 ‐4.01183326 ‐5.39313619
3.44113633 ‐5.45680453 ‐3.0770877 ‐2.7001804 ‐3.55570753 ‐3.44694563 ‐0.32061693
2.82188894 0.61346347 1.16135771 ‐2.35578418 ‐3.72139059 ‐2.98218543 0.42421938
2.73388181 ‐5.13646062 ‐4.06877828 ‐2.52664949 ‐4.19508209 ‐3.09326379 ‐5.93914837
0.66460965 ‐5.77944629 ‐3.69121449 ‐3.19939191 ‐4.85232085 ‐4.07962513 ‐6.36243669
3.14263496 ‐1.40810079 ‐0.63658925 ‐2.70483684 ‐5.36441778 ‐3.16842683 ‐5.11142493
2.90791579 ‐0.34558712 ‐0.32270805 ‐2.01657422 ‐3.56686308 ‐3.65561904 ‐1.05333097
3.34427364 ‐5.83146455 ‐3.32731817 ‐2.71318542 ‐3.71304277 ‐4.45622919 ‐5.09799858
2.81043185 ‐1.13407262 1.42082953 ‐2.60000545 ‐4.62199062 ‐3.19636451 ‐5.84900597
3.21558724 ‐3.4496232 ‐0.33726151 ‐2.93416856 ‐5.06411598 ‐3.70242943 ‐5.65807051
3.18613361 ‐5.23875567 ‐4.07230189 ‐2.913198 ‐5.18413434 ‐3.00642195 ‐5.4723922
3.44820987 ‐1.66531409 ‐2.28798783 ‐2.8709439 ‐6.00756069 ‐3.86445049 0.41581834
2.48409622 ‐0.67234665 ‐1.08136635 ‐2.69775916 ‐5.39026522 ‐3.56898379 ‐2.34136624
2.16619852 ‐0.1543251 ‐2.26505404 ‐2.77486552 ‐5.7205482 ‐3.89216909 ‐1.66124008
3.24618955 ‐4.74142391 ‐3.28586035 ‐3.31037581 ‐4.85724706 ‐3.4112344 ‐3.12224108
2.32378567 ‐2.58388747 ‐0.83689265 ‐2.70368745 ‐4.96182627 ‐4.08350437 ‐4.95096225
2.28588178 0.74408053 ‐1.9702878 ‐2.65831666 ‐4.90146182 ‐3.52780408 0.63199825
1.20199976 ‐1.38362635 ‐0.58162112 ‐2.88103623 ‐6.60725706 ‐3.65360634 ‐1.12523356
2.3880506 ‐5.06856362 ‐4.0461551 ‐2.8571423 ‐6.00439438 ‐4.07601063 ‐5.3848478
3.70668013 1.27450719 1.94112029 ‐2.46263234 ‐4.94171091 ‐3.05302158 0.76993712
3.08919947 ‐0.87526224 ‐3.02546087 ‐2.79545906 ‐4.62032765 ‐3.77828715 ‐1.74865555
3.02652778 ‐4.88059467 ‐2.88762087 ‐2.88346891 ‐5.54049374 ‐3.43356373 ‐0.88963608
2.3167151 ‐6.25993852 ‐4.39321899 ‐2.64564657 ‐4.76744508 ‐3.67856187 ‐5.4486569
1.33283507 ‐5.61635015 ‐4.42281623 ‐2.81170257 ‐6.46364576 ‐3.75123279 ‐5.07603589
3.27303396 ‐3.86585343 ‐3.91423724 ‐2.76782656 ‐4.51488406 ‐3.30858656 ‐4.6445519
3.61751483 ‐4.86290389 ‐4.02219692 ‐3.01745358 ‐3.58586957 ‐3.28147438 ‐5.63117345
2.37131021 0.69547321 1.4209702 ‐2.71216757 ‐4.37096749 ‐3.56988193 0.76665608
2.15220023 ‐5.79330008 ‐3.99742866 ‐3.1826955 ‐5.08113128 ‐4.96988646 ‐4.0138151
2.53451581 ‐4.38254853 ‐4.02884559 ‐2.98949671 ‐4.6835968 ‐4.0250375 ‐4.14876079
2.10487698 ‐5.01763062 ‐3.57749339 ‐3.05970762 ‐5.03481603 ‐4.40589632 ‐3.18849772
2.41455455 ‐3.31050485 ‐3.26433807 ‐3.44278983 ‐4.5700721 ‐4.7746709 ‐3.40151905
cg25946389 cg26201213 cg26950715
‐1.31539602 0.37808312 2.67231699
‐3.18590307 0.14387418 0.22858595
0.37786826 1.17990638 2.31792686
‐2.41381142 1.26503045 3.10006892
‐2.22983247 ‐0.78563742 2.75928456
1.98829618 2.29960912 2.99044665
‐1.04122034 1.4036828 2.99951142
0.50982262 1.34911124 2.555347
‐0.76605975 0.27622057 1.86100107
1.66115235 1.51127673 2.49217958
0.08727932 1.21532413 2.62436285
2.59785201 2.77829221 2.98240956
‐2.15052644 1.1235314 0.24059181
‐1.64585632 ‐0.62654785 2.92256779
‐0.45425832 0.48949995 2.7793284
‐2.57619041 0.26905685 1.90730778
‐1.69421395 ‐1.27767504 1.78920691
‐0.23220507 1.70670687 3.0212675
‐0.77391098 2.23344448 2.64047554
‐2.74537386 0.93875095 2.15604699
‐1.23151856 2.37866421 2.45890708
‐1.87839769 1.31808287 2.10579103
‐0.19704359 0.35120901 2.0986126
0.0392484 0.22241532 2.72841408
‐1.97555809 0.55570136 2.29555458
‐1.23549407 1.1522079 2.97736721
‐1.47000427 0.7926917 1.39062143
‐1.29733312 0.15703587 2.10307872
1.64637059 2.02960727 2.77022907
‐1.98816962 1.11153676 1.26876049
0.87672255 2.22569378 2.57197575
0.29032767 0.43780317 2.601111
‐1.73043558 1.89784503 3.20495338
‐1.2820553 0.50266061 2.76791135
‐2.88777728 ‐0.7491149 1.25206166
1.08005833 1.13724675 0.9719961
2.39896527 ‐0.00910962 2.72220672
‐2.70159929 ‐0.44805929 2.36239768
2.05937794 1.66117858 2.77142745
1.42856278 1.48522522 1.87439837
‐2.61094673 1.59368862 2.7372781
‐2.77796506 ‐1.01979562 3.03537953
‐1.69263944 1.78168208 2.47273265
0.38470503 0.96635088 2.54051367
‐1.69807386 1.44854122 3.06987849
‐2.4904372 2.14750507 ‐0.27888976
‐2.58115433 0.30813909 2.26104889
‐2.40742904 1.70265218 2.98546761
1.26332694 1.93157373 3.2807547
0.74143282 0.7708461 2.08878668
0.14347137 0.25099092 2.49997646
‐0.54432052 0.5919029 2.87505356
‐0.59573066 1.07350817 2.58878666
1.65475319 1.72364451 2.7547123
0.31514194 0.21161705 2.40772502
‐2.17876654 0.2047283 2.97749289
2.45743296 2.23261736 3.07678801
1.78510514 1.99865983 1.40287631
1.3633976 1.1182408 2.66364419
‐2.64050063 0.52977147 2.76354677
‐2.12628886 ‐0.88936657 1.73754487
‐1.89915282 1.80006355 2.56636696
‐1.92114044 2.22426048 3.41641987
1.47911315 1.93628826 3.06556202
‐1.91221796 0.54001165 1.82314228
‐1.54424868 0.66278214 2.35522452
‐1.33413421 0.73118425 2.38546181
‐1.10894277 0.88429417 2.52858859
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Table S2. MGMT Prediction Models for M-GBM dataset
Probe_ID Code_Fig1 MAP_INFO Present in 27K Design type (450K) rpearson
cg26950715 1 131264786 no II 0.057
cg02330106 2 131264840 yes II -0.381
cg12575438 3 131264846 no II -0.266
cg02022136 4 131265059 no I -0.304
cg23998405 5 131265067 no I -0.180
cg01341123 6 131265071 no II -0.203
cg25946389 7 131265073 yes II -0.303
cg14194875 8 131265137 no I -0.435
cg00618725 9 131265159 no I -0.396
cg12434587 10 131265209 yes I -0.475
cg16215402 11 131265405 no I -0.276
cg18026026 12 131265411 no I -0.203
cg05068430 13 131265416 no I 0.031
cg19706602 14 131265435 yes I -0.167
cg02802904 15 131265470 no I -0.363
cg12981137 16 131265575 yes I -0.497
cg02941816 17 131265696 yes II -0.459
cg26201213 18 131265796 yes II -0.500
Models
STP27  -  -  -  -  -
STP450  -  -  -  -  -
see Supplement for description of abbreviations and Illumina webpage for description of probes and d
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rspearman p AIC AICc BIC CovPat MVIF CutOff Sens Spec
0.015 1 96.099 96.159 100.538 0.000  - 0.445 0.656 0.556
-0.429 1 92.228 92.289 96.667 0.000  - 0.392 0.844 0.444
-0.233 1 98.029 98.090 102.468 0.000  - 0.475 0.125 0.972
-0.338 1 82.781 82.842 87.220 0.000  - 0.509 0.625 0.833
-0.233 1 86.894 86.954 91.333 0.015  - 0.518 0.594 0.833
-0.244 1 87.279 87.339 91.718 0.000  - 0.569 0.531 0.889
-0.358 1 84.081 84.141 88.520 0.000  - 0.553 0.625 0.861
-0.476 1 57.606 57.667 62.045 0.029  - 0.377 0.906 0.861
-0.433 1 63.047 63.108 67.486 0.015  - 0.599 0.750 0.944
-0.543 1 47.511 47.571 51.950 0.029  - 0.355 0.875 0.944
-0.243 1 82.450 82.511 86.889 0.000  - 0.338 0.875 0.500
-0.184 1 97.474 97.535 101.913 0.000  - 0.489 0.406 0.750
0.026 1 96.156 96.217 100.595 0.000  - 0.523 0.438 0.833
-0.178 1 93.883 93.944 98.322 0.000  - 0.422 0.813 0.472
-0.333 1 70.956 71.017 75.396 0.015  - 0.609 0.594 0.972
-0.571 1 37.644 37.704 42.083 0.029  - 0.545 0.906 0.944
-0.453 1 83.758 83.819 88.197 0.015  - 0.387 0.813 0.667
-0.530 1 95.390 95.451 99.829 0.000  - 0.576 0.281 0.917
 - 2 36.143 36.327 42.801 0.029 1.160 0.358 0.969 0.889
 - 4 36.621 37.256 47.718 0.029 8.884 0.509 0.938 0.944
esign typ
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Kappa Accuracy
0.210 0.603
0.281 0.632
0.102 0.574
0.463 0.735
0.432 0.721
0.428 0.721
0.492 0.750
0.765 0.882
0.702 0.853
0.822 0.912
0.366 0.676
0.159 0.588
0.277 0.647
0.278 0.632
0.578 0.794
0.852 0.926
0.474 0.735
0.205 0.618
0.853 0.926
0.882 0.941
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Table S4. Annotation of TCGA-GBM dataset
bcr_patient_barcode dataset Subtype CIMP MGMT-STP27 (response)
TCGA-19-0964 HM-27K Classical 0 0.998330419
TCGA-06-2565 HM-27K NA 0 0.997486082
TCGA-06-0877 HM-27K Classical 0 0.908505291
TCGA-02-0007 HM-27K Classical 0 0.278962809
TCGA-02-0009 HM-27K Classical 0 0.538506655
TCGA-02-0021 HM-27K Classical 0 0.754682945
TCGA-06-0122 HM-27K Mesenchymal 0 0.156252119
TCGA-12-1098 HM-27K Classical 0 0.001862951
TCGA-12-3648 HM-27K Classical 0 0.682345526
TCGA-14-0783 HM-27K Mesenchymal 0 0.995492886
TCGA-14-0817 HM-27K Neural 0 0.007156551
TCGA-14-1396 HM-27K Mesenchymal 0 0.994618723
TCGA-14-1402 HM-27K NA 0 0.981814064
TCGA-16-1062 HM-27K Classical 0 0.751231943
TCGA-19-1789 HM-27K Classical 0 0.997113054
TCGA-27-1833 HM-27K Classical 0 0.02863833
TCGA-28-1750 HM-27K Mesenchymal 0 0.058666463
TCGA-19-1390 HM-27K Proneural 0 0.998021697
TCGA-14-0790 HM-27K NA 0 0.979065038
TCGA-12-1598 HM-27K Proneural 0 0.996178567
TCGA-06-2563 HM-27K NA 0 0.995770084
TCGA-06-0125 HM-27K Classical 0 0.998725868
TCGA-12-3646 HM-27K Proneural 0 0.996766016
TCGA-19-0957 HM-27K Proneural 0 0.26276641
TCGA-28-1746 HM-27K Proneural 0 0.996587035
TCGA-02-0037 HM-27K Classical 0 0.179789127
TCGA-02-0083 HM-27K Neural 0 0.998238686
TCGA-06-0876 HM-27K Classical 0 0.994714849
TCGA-28-2509 HM-27K NA 0 0.99144555
TCGA-32-1982 HM-27K NA 0 0.990831092
TCGA-16-1060 HM-27K Mesenchymal 0 0.055697552
TCGA-14-0786 HM-27K Classical 0 0.972938253
TCGA-06-0155 HM-27K Mesenchymal 0 0.016997011
TCGA-14-1829 HM-27K NA 0 0.009230552
TCGA-28-2514 HM-27K NA 0 0.009377393
TCGA-12-0821 HM-27K Neural 0 0.01386001
TCGA-14-1455 HM-27K Proneural 0 0.958310211
TCGA-26-1440 HM-27K Classical 0 0.049201815
TCGA-16-0861 HM-27K Mesenchymal 0 0.107165507
TCGA-02-0113 HM-27K Neural 0 0.410497982
TCGA-06-2566 HM-27K NA 0 0.293244442
TCGA-02-0027 HM-27K Classical 0 0.527775567
TCGA-02-0069 HM-27K Proneural 0 0.970083936
TCGA-06-0875 HM-27K Proneural 0 0.040611377
TCGA-06-1801 HM-27K Proneural 0 0.175264197
TCGA-06-2558 HM-27K NA 0 0.009365492
TCGA-12-0826 HM-27K Classical 0 0.225857217
TCGA-12-1088 HM-27K Mesenchymal 0 0.065267535
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TCGA-12-3653 HM-27K Classical 0 0.039718838
TCGA-15-1447 HM-27K Proneural 0 0.992564055
TCGA-19-0960 HM-27K Proneural 0 0.998604282
TCGA-27-1836 HM-27K NA 0 0.973357516
TCGA-27-1838 HM-27K NA 0 0.181813527
TCGA-28-1755 HM-27K NA 0 0.004661451
TCGA-14-1459 HM-27K NA 0 0.941975859
TCGA-14-1454 HM-27K Proneural 0 0.010033461
TCGA-12-3644 HM-27K Neural 0 0.968177473
TCGA-12-1099 HM-27K Proneural 0 0.025634894
TCGA-02-0001 HM-27K Mesenchymal 0 0.116894242
TCGA-02-0006 HM-27K Mesenchymal 0 0.354295582
TCGA-02-0074 HM-27K Proneural 0 0.23886496
TCGA-02-0085 HM-27K Mesenchymal 0 0.990359033
TCGA-02-0086 HM-27K Mesenchymal 0 0.523972007
TCGA-06-0147 HM-27K Mesenchymal 0 0.949905212
TCGA-06-2561 HM-27K NA 0 0.069567473
TCGA-12-1093 HM-27K Mesenchymal 0 0.001526901
TCGA-12-1095 HM-27K Mesenchymal 0 0.002243917
TCGA-12-1599 HM-27K Neural 0 0.863103528
TCGA-14-1034 HM-27K Mesenchymal 0 0.935653571
TCGA-14-1037 HM-27K Mesenchymal 0 0.072660405
TCGA-14-2554 HM-27K NA 0 0.102677937
TCGA-14-2555 HM-27K Classical 0 0.972693898
TCGA-19-0962 HM-27K Mesenchymal 0 0.993504187
TCGA-19-1791 HM-27K Classical 0 0.034568769
TCGA-26-1443 HM-27K Classical 0 0.983663742
TCGA-27-1835 HM-27K NA 0 0.951404907
TCGA-28-1751 HM-27K Mesenchymal 0 0.037376984
TCGA-28-2506 HM-27K NA 0 0.948647263
TCGA-28-2513 HM-27K NA 0 0.009338676
TCGA-32-2616 HM-27K Mesenchymal 0 0.965870228
TCGA-28-1752 HM-27K Neural 0 0.989987363
TCGA-27-2526 HM-27K NA 0 0.011694456
TCGA-27-1832 HM-27K Mesenchymal 0 0.029674946
TCGA-19-2625 HM-27K Mesenchymal 0 0.048536409
TCGA-19-1786 HM-27K Classical 0 0.002849194
TCGA-02-0060 HM-27K Proneural 0 0.975086192
TCGA-02-0057 HM-27K Mesenchymal 0 0.129337636
TCGA-02-0055 HM-27K Mesenchymal 0 0.218941228
TCGA-02-0054 HM-27K Mesenchymal 0 0.916127822
TCGA-02-0038 HM-27K Classical 0 0.164440024
TCGA-02-0003 HM-27K Proneural 0 0.115882884
TCGA-02-0033 HM-27K Mesenchymal 0 0.991631635
TCGA-02-0034 HM-27K Mesenchymal 0 0.183508551
TCGA-06-1086 HM-27K Mesenchymal 0 0.006302393
TCGA-06-2569 HM-27K NA 0 0.007729294
TCGA-12-0822 HM-27K Mesenchymal 0 0.703784561
TCGA-12-1089 HM-27K Classical 0 0.038041334
TCGA-12-1097 HM-27K Neural 0 0.00471193
TCGA-14-0865 HM-27K Proneural 0 0.914291794
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TCGA-14-3477 HM-27K Proneural 0 0.015370591
TCGA-16-1055 HM-27K Mesenchymal 0 0.01723816
TCGA-19-1388 HM-27K Mesenchymal 0 0.976336377
TCGA-19-1389 HM-27K Mesenchymal 0 0.166154656
TCGA-27-1830 HM-27K Mesenchymal 0 0.467201477
TCGA-27-1831 HM-27K NA 0 0.03478327
TCGA-28-1757 HM-27K Classical 0 0.934500058
TCGA-32-1986 HM-27K NA 0 0.026688194
TCGA-32-2615 HM-27K Mesenchymal 0 0.049972179
TCGA-41-2571 HM-27K Proneural 0 0.06706634
TCGA-28-1747 HM-27K NA 0 0.920882681
TCGA-28-1745 HM-27K Mesenchymal 0 0.267675593
TCGA-27-2527 HM-27K NA 0 0.860753193
TCGA-27-2519 HM-27K NA 0 0.006198627
TCGA-27-1834 HM-27K Neural 0 0.972997501
TCGA-26-1438 HM-27K Mesenchymal 0 0.054068739
TCGA-19-2624 HM-27K Proneural 0 0.036458851
TCGA-19-1385 HM-27K Mesenchymal 0 0.989580984
TCGA-19-0955 HM-27K Classical 0 0.474639973
TCGA-14-1827 HM-27K Neural 0 0.954473406
TCGA-14-1451 HM-27K Proneural 0 0.002043454
TCGA-14-0871 HM-27K Proneural 0 0.00332835
TCGA-14-0736 HM-27K NA 0 0.039167731
TCGA-12-1096 HM-27K Mesenchymal 0 0.016444267
TCGA-12-1090 HM-27K Classical 0 0.995328493
TCGA-06-2567 HM-27K NA 0 0.99157017
TCGA-06-2564 HM-27K NA 0 0.06098418
TCGA-06-1087 HM-27K Proneural 0 0.026764717
TCGA-06-1084 HM-27K Mesenchymal 0 0.937397752
TCGA-06-0882 HM-27K Neural 0 0.00842615
TCGA-06-0881 HM-27K Mesenchymal 0 0.006849411
TCGA-06-0878 HM-27K Mesenchymal 0 0.023738864
TCGA-06-0141 HM-27K Mesenchymal 0 0.123520667
TCGA-06-0139 HM-27K Mesenchymal 0 0.136731892
TCGA-06-0130 HM-27K Mesenchymal 0 0.156141827
TCGA-02-2470 HM-27K NA 0 0.015536742
TCGA-02-0115 HM-27K Neural 0 0.964247289
TCGA-02-0107 HM-27K Mesenchymal 0 0.112107864
TCGA-02-0052 HM-27K Neural 0 0.331725028
TCGA-02-0047 HM-27K Proneural 0 0.118340395
TCGA-02-0024 HM-27K Proneural 0 0.105293533
TCGA-02-0011 HM-27K Proneural 0 0.965415245
TCGA-02-2466 HM-27K NA 0 0.032211745
TCGA-06-0143 HM-27K Mesenchymal 0 0.113077986
TCGA-06-1800 HM-27K Mesenchymal 0 0.994141188
TCGA-12-1091 HM-27K Classical 0 0.969705326
TCGA-12-1092 HM-27K Mesenchymal 0 0.925135819
TCGA-14-1825 HM-27K Proneural 0 0.001534259
TCGA-19-0963 HM-27K Neural 0 0.150853644
TCGA-32-1976 HM-27K NA 0 0.991114157
TCGA-41-2573 HM-27K Proneural 0 0.990443232
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TCGA-41-2575 HM-27K Proneural 0 0.019756425
TCGA-27-1837 HM-27K NA 0 0.989016549
TCGA-14-1401 HM-27K Proneural 0 0.957618369
TCGA-14-0813 HM-27K Proneural 0 0.994084289
TCGA-12-3651 HM-27K Neural 0 0.989974577
TCGA-12-1602 HM-27K Proneural 0 0.994455645
TCGA-06-2559 HM-27K NA 0 0.996494286
TCGA-02-0046 HM-27K Proneural 0 0.996478078
TCGA-02-0043 HM-27K Classical 0 0.999492021
TCGA-02-0064 HM-27K Mesenchymal 0 0.991298598
TCGA-02-0071 HM-27K Mesenchymal 0 0.251844354
TCGA-02-0075 HM-27K Mesenchymal 0 0.994161069
TCGA-02-0099 HM-27K Mesenchymal 0 0.996412984
TCGA-06-0124 HM-27K Mesenchymal 0 0.992616714
TCGA-06-0133 HM-27K Neural 0 0.203097319
TCGA-06-0879 HM-27K Classical 0 0.991814815
TCGA-12-0828 HM-27K Neural 0 0.428052248
TCGA-12-0829 HM-27K Mesenchymal 0 0.974353776
TCGA-12-1094 HM-27K Classical 0 0.010609353
TCGA-14-0867 HM-27K Mesenchymal 0 0.996494219
TCGA-14-1794 HM-27K Proneural 0 0.035993564
TCGA-16-0848 HM-27K Proneural 0 0.97892215
TCGA-16-1063 HM-27K NA 0 0.048338267
TCGA-19-2621 HM-27K Classical 0 0.99300517
TCGA-26-1799 HM-27K Neural 0 0.088293165
TCGA-28-1753 HM-27K NA 0 0.024318304
TCGA-32-1970 HM-27K NA 0 0.015561859
TCGA-32-2632 HM-27K Mesenchymal 0 0.071135652
TCGA-41-3392 HM-27K Neural 0 0.060745459
TCGA-28-2502 HM-27K NA 0 0.07056148
TCGA-28-1760 HM-27K Mesenchymal 0 0.050825763
TCGA-19-2623 HM-27K Mesenchymal 0 0.957940907
TCGA-19-1386 HM-27K Classical 0 0.04241051
TCGA-16-1056 HM-27K Classical 0 0.078627608
TCGA-15-1446 HM-27K Classical 0 0.023796181
TCGA-14-0866 HM-27K Neural 0 0.994101497
TCGA-14-0789 HM-27K Mesenchymal 0 0.986369689
TCGA-12-3652 HM-27K Classical 0 0.041552682
TCGA-12-3650 HM-27K Neural 0 0.192357093
TCGA-12-0820 HM-27K Classical 0 0.306882803
TCGA-06-0169 HM-27K Mesenchymal 0 0.32151847
TCGA-06-0148 HM-27K NA 0 0.186509872
TCGA-02-0089 HM-27K Neural 0 0.418865701
TCGA-02-2485 HM-27K NA 0 0.007420642
TCGA-02-2486 HM-27K NA 0 0.06724384
TCGA-06-0126 HM-27K Classical 0 0.184693523
TCGA-12-0670 HM-27K Neural 0 0.753622856
TCGA-14-0787 HM-27K Classical 0 0.992587256
TCGA-14-0812 HM-27K Neural 0 0.884922336
TCGA-14-1452 HM-27K Mesenchymal 0 0.980145793
TCGA-14-1795 HM-27K Proneural 0 0.989878983
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TCGA-16-0846 HM-27K Proneural 0 0.995150403
TCGA-19-1387 HM-27K Proneural 0 0.993378926
TCGA-19-1787 HM-27K Mesenchymal 0 0.995594055
TCGA-19-2620 HM-27K Classical 0 0.989413262
TCGA-27-2518 HM-27K NA 0 0.164002834
TCGA-27-2524 HM-27K NA 0 0.017420817
TCGA-27-2528 HM-27K NA 0 0.635996922
TCGA-32-2634 HM-27K Proneural 0 0.996721382
TCGA-32-2638 HM-27K Classical 0 0.979207886
TCGA-28-1749 HM-27K Classical 0 0.127855734
TCGA-27-2523 HM-27K NA 0 0.993759561
TCGA-19-1392 HM-27K Proneural 0 0.986221824
TCGA-14-1453 HM-27K Classical 0 0.011306363
TCGA-12-3649 HM-27K Neural 0 0.022314196
TCGA-12-1600 HM-27K Classical 0 0.061901421
TCGA-06-2562 HM-27K NA 0 0.02872698
TCGA-06-2557 HM-27K NA 0 0.178002532
TCGA-06-1802 HM-27K Mesenchymal 0 0.989937375
TCGA-02-0116 HM-27K Mesenchymal 0 0.241091106
TCGA-02-0102 HM-27K Classical 0 0.19332825
TCGA-02-0014 HM-27K Proneural 1 0.117710694
TCGA-02-0028 HM-27K Proneural 1 0.998335898
TCGA-06-1805 HM-27K Proneural 1 0.224773517
TCGA-06-2570 HM-27K NA 1 0.980971043
TCGA-12-0827 HM-27K Mesenchymal 1 0.805783854
TCGA-14-1456 HM-27K NA 1 0.556609715
TCGA-14-1458 HM-27K Proneural 1 0.958064164
TCGA-19-1788 HM-27K Proneural 1 0.983781382
TCGA-19-2629 HM-27K Proneural 1 0.049523516
TCGA-28-1756 HM-27K NA 1 0.989170307
TCGA-27-2521 HM-27K NA 1 0.998397621
TCGA-16-0849 HM-27K Proneural 1 0.463153085
TCGA-14-1821 HM-27K Proneural 1 0.943672808
TCGA-06-0129 HM-27K Proneural 1 0.977648165
TCGA-06-0128 HM-27K Proneural 1 0.977943137
TCGA-02-2483 HM-27K NA 1 0.966409576
TCGA-02-0080 HM-27K Proneural 1 0.85690658
TCGA-02-0010 HM-27K Proneural 1 0.183573273
TCGA-16-0850 HM-27K Proneural 1 0.078993973
TCGA-02-0114 HM-27K Proneural 1 0.993850031
TCGA-06-5414 HM-450K Classical NA 0.026411471
TCGA-06-5415 HM-450K Classical NA 0.011341718
TCGA-06-5416 HM-450K Proneural NA 0.13975203
TCGA-06-5417 HM-450K Proneural NA 0.976177539
TCGA-06-5418 HM-450K NA NA 0.0861036
TCGA-12-5295 HM-450K Neural NA 0.992547423
TCGA-12-5299 HM-450K Classical NA 0.057375593
TCGA-12-5301 HM-450K Neural NA 0.992653037
TCGA-26-5132 HM-450K Classical NA 0.994449034
TCGA-26-5133 HM-450K Proneural NA 0.033480542
TCGA-26-5134 HM-450K Proneural NA 0.028343968
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TCGA-26-5135 HM-450K Proneural NA 0.910096282
TCGA-26-5136 HM-450K Mesenchymal NA 0.942378446
TCGA-26-5139 HM-450K Mesenchymal NA 0.051294466
TCGA-28-5204 HM-450K Neural NA 0.035255743
TCGA-28-5207 HM-450K NA NA 0.033872393
TCGA-28-5208 HM-450K NA NA 0.995944053
TCGA-28-5209 HM-450K Mesenchymal NA 0.997280274
TCGA-28-5213 HM-450K NA NA 0.016157843
TCGA-28-5214 HM-450K Mesenchymal NA 0.244304771
TCGA-28-5215 HM-450K Mesenchymal NA 0.868875196
TCGA-28-5216 HM-450K Mesenchymal NA 0.034636178
TCGA-28-5218 HM-450K Mesenchymal NA 0.022101363
TCGA-28-5219 HM-450K Classical NA 0.966226487
TCGA-28-5220 HM-450K Classical NA 0.025217251
TCGA-32-5222 HM-450K Proneural NA 0.992933499
TCGA-76-4925 HM-450K Proneural NA 0.998237477
TCGA-76-4926 HM-450K Mesenchymal NA 0.018142488
TCGA-76-4927 HM-450K Neural NA 0.035468836
TCGA-76-4928 HM-450K Classical NA 0.74628518
TCGA-76-4929 HM-450K Neural NA 0.996332934
TCGA-76-4931 HM-450K Classical NA 0.022155511
TCGA-76-4932 HM-450K Proneural NA 0.971405986
TCGA-76-4934 HM-450K Proneural NA 0.897547642
TCGA-76-4935 HM-450K Proneural NA 0.927768584
TCGA-06-0650 HM-450K Mesenchymal NA 0.094094779
TCGA-06-1804 HM-450K Classical NA 0.98942752
TCGA-06-5408 HM-450K Classical NA 0.029608161
TCGA-06-5410 HM-450K Mesenchymal NA 0.672662967
TCGA-06-5411 HM-450K Neural NA 0.152043491
TCGA-06-5412 HM-450K Mesenchymal NA 0.964140825
TCGA-06-5413 HM-450K Neural NA 0.020156637
TCGA-06-5856 HM-450K Proneural NA 0.222756545
TCGA-06-5858 HM-450K Mesenchymal NA 0.452235411
TCGA-06-5859 HM-450K Neural NA 0.014145626
TCGA-06-6389 HM-450K Proneural NA 0.957375937
TCGA-06-6390 HM-450K Classical NA 0.039438945
TCGA-06-6391 HM-450K Proneural NA 0.46199731
TCGA-14-0781 HM-450K Mesenchymal NA 0.144585406
TCGA-15-1444 HM-450K Proneural NA 0.923945149
TCGA-19-5947 HM-450K Mesenchymal NA 0.054430349
TCGA-19-5950 HM-450K Classical NA 0.987087377
TCGA-19-5951 HM-450K Classical NA 0.136777673
TCGA-19-5952 HM-450K Classical NA 0.026630345
TCGA-19-5954 HM-450K Classical NA 0.654578442
TCGA-19-5955 HM-450K Mesenchymal NA 0.742994446
TCGA-19-5956 HM-450K Proneural NA 0.226888673
TCGA-19-5958 HM-450K Classical NA 0.048196133
TCGA-19-5959 HM-450K Classical NA 0.994068631
TCGA-19-5960 HM-450K Proneural NA 0.143723814
TCGA-26-1442 HM-450K Proneural NA 0.898414934
TCGA-28-2501 HM-450K Mesenchymal NA 0.961299912
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TCGA-28-2510 HM-450K Neural NA 0.076260518
TCGA-28-6450 HM-450K Classical NA 0.16611129
TCGA-32-1979 HM-450K Neural NA 0.467259512
TCGA-32-1980 HM-450K Neural NA 0.036993892
TCGA-41-5651 HM-450K Proneural NA 0.99187475
TCGA-76-6191 HM-450K Proneural NA 0.021235479
TCGA-76-6192 HM-450K Proneural NA 0.040673492
TCGA-76-6193 HM-450K Mesenchymal NA 0.029230222
TCGA-76-6282 HM-450K Mesenchymal NA 0.102776239
TCGA-76-6285 HM-450K Proneural NA 0.218056739
TCGA-81-5910 HM-450K Classical NA 0.029113593
TCGA-87-5896 HM-450K Classical NA 0.105310671
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CpG island in MGMT promoter region
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